Annual Secretarial Compliance Report for the year ended 31.03.2026 pursuant to Regulation 24A of SEBI (LODR) Regulations, 2018.
Change in Management by way of appointment of Additional Directors and Internal Auditor.
Audited Financial Results for the Quarter and Year ended 31.03.2026.
Outcome of the Board meeting held on 23rd May, 2026.
1. Audited Financial Results for the quarter and year ended 31.03.2026 2. Audit Report for the year ended 31.03.2026 3. Any other item with the permission of chair
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Oxygenta Pharmaceutical Ltd 2 CIN NO. L24110TG1990PLC012038 3 Report filed for FY 2025-2026 Details of the Current block (all figures in Rs crore): 4 2 – year block period (Specify financial years)* FY 2025-26, 2026-27 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T – 1) carried forward to FY (T) (d) NIL 8Quantum of (d), which has been met from (c)(e)* NIL 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T – 1) which was carried forward to FY(T)}(f) = (b) – [(c) – (e)]{ If the calculated value is zero or negative, write “nil”}* NIL Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 – year Block period (Specify financial years)FY 2025-26, 2024-25 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) – (e)}#0.00 Name of the Company Secretary :-KUMKUM BAJAJDesignation :-COMPANY SECRETARY AND COMPLIANCE OFFICER Name of the Chief Financial Officer :- PRASAD REDDY BATTINAPATLA Designation : -CHIEF FINANCIAL OFFICER Date: 27/04/2026
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyOxygenta Pharmaceutical Ltd 2CIN NO.L24110TG1990PLC012038 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 1073089940.31 4Highest Credit Rating during the previous FY NIL 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: KUMKUM BAJAJ Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: cs@decipherlabs.in Name of the Chief Financial Officer: PRASAD REDDY BATTINAPATLA Designation: CHIEF FINANCIAL OFFICER EmailId: prasadb@virupaksha.com Date: 27/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Compliance as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended 31st March, 2026
Closure of Trading Window for the period ending on 31.03.2026.
Disclosure under Regulation 30 of SEBI (Listing Obligations and Discloure Requirements) Regulations, 2015.
| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 13.08 | 9.15 | 10.55 | 12.62 | 14.01 | 33.21 | 49.47 | 15.13 | 14.30 | 33.93 | 49.61 | 37.00 |
| YOY Revenue Growth % | 115.9% | 16.53% | 28.91% | 83.87% | 7.11% | 262.91% | 368.77% | 19.92% | 2.12% | 2.18% | 0.3% | 144.45% |
| Other Income | 0.00 | 0.03 | 0.01 | 0.02 | 0.75 | 0.49 | 0.05 | 0.17 | -0.06 | 0.00 | 0.17 | 0.02 |
| Total Income | 13.08 | 9.18 | 10.57 | 12.64 | 14.75 | 33.69 | 49.52 | 15.30 | 14.25 | 33.93 | 49.79 | 37.02 |
| Total Expenses + | 16.23 | 12.67 | 13.40 | 15.46 | 17.53 | 38.66 | 53.04 | 23.44 | 20.68 | 40.26 | 51.07 | 39.53 |
| Cost of Materials Consumed | 11.68 | 6.25 | 9.04 | 10.66 | 7.94 | 37.61 | 44.03 | 15.66 | 16.97 | 31.17 | 46.54 | 23.40 |
| Employee Benefit Expense | 0.33 | 0.24 | 5.25 | 1.48 | 1.40 | 1.83 | 2.19 | 2.00 | 2.03 | 1.89 | 1.72 | 1.95 |
| Other Expenses | 3.19 | 3.33 | 0.00 | 2.92 | 3.94 | 3.88 | 5.17 | 5.01 | 4.41 | 4.58 | 4.58 | 4.25 |
| Operating Profit | -3.15 | -3.52 | -2.85 | -2.84 | -3.52 | -5.45 | -3.58 | -8.31 | -6.38 | -6.33 | -1.45 | -2.53 |
| OPM % | -24.1% | -38.5% | -27% | -22.5% | -25.2% | -16.4% | -7.2% | -54.9% | -44.6% | -18.6% | -2.9% | -6.8% |
| Profit Before Tax + | -3.18 | -3.55 | -2.59 | -2.82 | -2.77 | -4.96 | -3.80 | -8.15 | -6.44 | -6.33 | -1.28 | -2.51 |
| Tax Expense | -0.02 | 0.23 | -10.60 | -1.45 | 0.08 | -1.03 | -1.65 | -2.04 | -1.51 | -1.48 | 0.42 | -0.40 |
| Tax % | - | - | - | - | - | - | - | - | - | - | - | - |
| Profit After Tax | -3.16 | -3.78 | 8.02 | -1.36 | -2.85 | -3.93 | -2.15 | -6.11 | -4.93 | -4.84 | -1.70 | -2.10 |
| EPS (Basic) | -0.87 | -1.12 | 2.55 | 0.39 | -0.81 | 1.07 | -0.60 | -1.65 | -1.33 | -1.32 | -0.45 | -0.57 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Revenue from Operations | 112.98 | 109.30 | 39.64 | 30.99 | 60.52 | 52.03 |
| YOY Revenue Growth % | 3.37% | 175.71% | 27.93% | -48.8% | 16.33% | - |
| Other Income | 0.29 | 1.31 | 0.04 | 0.02 | 0.00 | 0.09 |
| Total Income | 113.27 | 110.61 | 39.68 | 31.01 | 60.53 | 52.12 |
| Total Expenses + | 135.45 | 124.69 | 53.59 | 41.64 | 61.57 | 51.16 |
| Cost of Materials Consumed | 110.34 | 100.23 | 35.06 | 28.13 | 42.67 | 43.02 |
| Employee Benefit Expense | 7.64 | 6.90 | 5.99 | 1.12 | 0.33 | 0.73 |
| Other Expenses | 18.57 | 15.92 | 9.82 | 13.49 | 11.50 | 10.82 |
| Operating Profit | -22.47 | -15.39 | -13.95 | -10.66 | -1.04 | 0.86 |
| OPM % | -19.9% | -14.1% | -35.2% | -34.4% | -1.7% | 1.7% |
| Profit Before Exceptional | -22.18 | -14.08 | -13.91 | -10.64 | -1.04 | 0.96 |
| Exceptional Items | 0.00 | -0.27 | 0.04 | -0.73 | 0.55 | 2.19 |
| Profit Before Tax + | -22.18 | -14.35 | -13.87 | -11.37 | -0.49 | 3.14 |
| Tax Expense | -4.61 | -4.05 | -10.39 | 0.20 | 0.12 | 0.21 |
| Tax % | - | - | - | - | - | 6.8% |
| Profit After Tax | -17.57 | -10.30 | -3.48 | -11.57 | -0.61 | 2.93 |
| EPS (Basic) | -4.75 | -2.86 | -1.09 | -6.36 | -0.48 | 2.87 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Non-Current Assets + | 68.25 | 51.86 | 39.09 | 29.26 | 21.91 | 17.92 |
| Property, Plant & Equipment | 47.60 | 36.83 | 29.36 | 27.91 | 19.98 | 16.31 |
| Capital Work in Progress | 0.00 | 0.23 | 0.00 | 0.00 | 0.34 | 0.66 |
| Non-Current Investments | 0.47 | 0.05 | 0.00 | 0.05 | 0.05 | 0.05 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Assets + | 51.43 | 30.94 | 24.11 | 25.01 | 9.16 | 16.10 |
| Inventories | 29.42 | 20.51 | 13.72 | 11.71 | 7.28 | 12.11 |
| Trade Receivables | 10.03 | 5.10 | 7.36 | 10.16 | 1.27 | 1.61 |
| Cash and Cash Equivalents | 0.42 | 0.00 | 0.00 | 0.02 | 0.16 | 0.45 |
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| LIABILITIES & EQUITY | ||||||
| Total Equity | -42.69 | -25.64 | -20.12 | -46.20 | -34.63 | -38.02 |
| Equity Share Capital | 36.98 | 36.98 | 33.48 | 14.20 | 14.20 | 10.20 |
| Other Equity | -79.67 | -62.62 | -53.61 | -60.40 | -48.83 | -48.22 |
| Non-Current Liabilities | 76.27 | 22.60 | 49.62 | 74.42 | 59.01 | 53.03 |
| Current Liabilities | 86.10 | 85.85 | 33.70 | 26.04 | 6.79 | 19.01 |
| Total Liabilities | 162.37 | 108.44 | 83.31 | 100.46 | 65.81 | 72.04 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Cash from Operating Activities | -27.75 | 2.60 | -13.05 | -5.41 | -2.93 | -10.77 |
| Cash from Investing Activities | -14.39 | -11.25 | -4.09 | -9.64 | -4.94 | -6.72 |
| Cash from Financing Activities | 42.56 | 8.67 | 17.13 | 15.00 | 7.58 | 17.81 |
| Net Increase/Decrease in Cash | 0.42 | 0.02 | -0.01 | -0.05 | -0.29 | 0.33 |